Mesoblast misses H1 estimates
Source: SeekingAlpha
2026-02-27 03:30:30 ET
More on Mesoblast
- Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
- Mesoblast: Real-World Data Validates The Bull Case For Ryoncil
- Mesoblast rises as Ryoncil sales climb 60% in December quarter
- Seeking Alpha’s Quant Rating on Mesoblast
- Historical earnings data for Mesoblast
Read the full article on Seeking Alpha
For further details see:
Mesoblast misses H1 estimates
Mesoblast Limited
NASDAQ: MESO
MESO Trading
-3.57% G/L:
$15.13 Last:
97,266 Volume:
$15.19 Open:
MESO Latest News
March 03, 2026 10:02:00 am
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
MESO Stock Data
$2,320,216,937
94,873,961
N/A
31
N/A
Biotechnology & Life Sciences
Healthcare
AU
Melbourne
